- Source type
- Government
- Access type
- Official
- Publisher
- U.S. Food and Drug Administration
- Date
- 2024-03-05
- Added
- 2026-07-06
- Updated
- 2026-07-06
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
94
U.S. health regulator
- Publisher type
- Regulator
- Bias profile
- Low
This source is strongest for regulatory status and safety and weaker for consumer context and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 98/100
- Primary Anchor
- Clinical outcomes
- 84/100
- Strong Support
- Mechanism
- 68/100
- Context Source
- Safety
- 95/100
- Primary Anchor
- Consumer context
- 68/100
- Context Source
- Trial discovery
- 68/100
- Context Source
Best used for
- Approvals
- Labels
- Safety communications
Weak for
- Comparative effectiveness
- Consumer experience
Used in Viral Vitalism
CGMs for Non-Diabetics: Metabolic Radar or Anxiety Subscription?
Roles: Regulatory status
FDA clears first over-the-counter continuous glucose monitor
Roles: Regulatory status
Show section-level references
Related studies
Related sources
FDA: First Over-the-Counter Continuous Glucose Monitor for Children
Canonicalized from rapid brief fda-otc-cgm-children-dexcom-stelo.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
EMA: Vyjuvek EPAR
European regulatory context for the therapy; not proof of Australian reimbursement or access.
- Trust score
- 94
- Publisher
- European Medicines Agency
- Access
- Publisher
- Usage
- 1 connection
FDA: aspartame and other sweeteners in food
FDA source for approved sweeteners, acceptable daily intake framing, and the FDA view on aspartame safety.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 4 connections
FDA: Vyjuvek product page
U.S. regulatory context for the therapy; not proof of Australian routine access.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
Hogan Lovells: FDA IND clearance support for Cockayne syndrome gene therapy
Regulatory-background source confirming FDA IND clearance support for the Riaan program.
- Trust score
- 60
- Publisher
- Hogan Lovells
- Access
- Publisher
- Usage
- 1 connection
San Francisco Chronicle: PRIMA retinal implant reporting
Patient-facing reporting; add primary device/trial source before publishing as a rapid brief.
- Trust score
- 60
- Publisher
- San Francisco Chronicle
- Access
- Publisher
- Usage
- 0 connections